Study design: Double blind, partial crossover. Objectives: To evaluate the analgesic activity of a novel cranial electrostimulus in people with spinal cord injury (SCI). Setting: Hereward College, a residential centre that provides educational facilities for students with disabilities. Methods: Subjects with SCI experiencing chronic pain were randomly assigned into two groups, one of which received sham and the other transcranial electrostimulation treatment (TCET) on two occasions daily for four successive days. After a`wash-out' period of 8 weeks all subjects returned and received the identical stimulus that the treated cohort received on the ®rst arm of the study. Results: Pain measurements applied before and after each session indicated that the pain decreased in the treated group to 51% of that reported at the commencement of treatment; reported pain intensity did not decrease signi®cantly in the sham treated subjects. The same (sham) subject group reported experiencing 59% of the pain at the end of the second arm of the study (TCET) as on the ®rst arm (sham). No signi®cant dierences were determined between the mood of all subjects estimated before and after each sham or TCET treatment session. The reported analgesic, and combined antidepressant and anxiolytic drug use in subjects receiving TCET on the second arm of the study, was 46% and 53% respectively of the average pre-study drug use. No similar decrease in the use of the drugs was noted in the same subjects after sham treatment on the ®rst arm of the study. Salivary cortisol determinations made prior to and after each sham and treatment session implicated this corticoid in the pain-relieving mode of action of the treatment, but could not be associated with any changes in mood. Subjects receiving TCET had signi®cantly higher urinary 3-methoxy-4-hydroxy-phenylglycol (MHPG) output after the TCET treatment period than sham stimulation, implicating increased central noradrenaline (NA) metabolism in the observed eects. Conclusion: The subjects reported less pain during, and immediately after receiving this transcranial treatment, although they were using less medication than when receiving sham treatment.
Introduction
The perception of pain is a complex process modulated by a number of factors 1 whose elucidation has led to improvements in the pharmacological approach to pain amelioration. 2 The types of pain associated with spinal cord injury (SCI) however, present a major therapeutic challenge. 3, 4 Recent surveys 5 ± 7 of SCI subjects in various countries indicate that more than 60% of the respondents experience chronic pain/dysaesthesiae, the majority of whom describe their pain as severe. Consequently, subjects with SCI tend to be maintained on high doses and/or multiple medications from relatively young ages. 8 Satisfaction, however, in particular with analgesic ecacy, is reportedly low 9 and depression is frequently diagnosed 6, 7 in SCI subjects.
The suering 10 experienced by people in chronic pain should be the therapeutic target, attenuating the stressors associated with the physiological/psychological adjustments to SCI. 6,7,9,11 ± 13 Management of associated complaints such as sleep disturbance, 13 speci®c type of pain 2 ± 5 or depression 6, 7 increases the reliance on medication, 8 some of which is contentious for long term use. 14 The most familiar non-pharmaceutical alternative for pain management, transcutaneous electrical nerve stimulation (TENS), is of limited use in chronic pain 15 such as that associated with SCI. A variant, spinal cord stimulation, has been used for 30 years, 16 but there remains a lack of consistent proof of ecacy and cost eectiveness, and some studies 17, 18 report the development of tolerance with resultant loss of analgesic ecacy.
For some time non-invasive transcranial electrostimulation treatment (TCET) has been administered to ameliorate the abstinence symptoms associated with withdrawal from addictive substances 19, 20 and management of depression. 21 There are few rigorous clinical studies to determine its value in pain management, however, although the antinociceptive action of a subperception species of TCET was demonstrated in various experimental antinociceptive models 22, 23 and extracellular recording techniques indicated that these transcranial stimuli modify noxious evoked responses in pain-processing regions of the brain of rats. 24, 25 This subperception stimulus is suited to clinical studies involving a double-blind crossover design. Furthermore, the reported anxiolytic 19, 20 mood-enhancing eects 21 attributed to TCET could oer additional bene®ts to SCI subjects, including lowering the management drug burden. Hence, total drug usage before, during and after sham or TCET was monitored as an additional indication of the ecacy of treatment (on the assumption subjects perceiving pain relief would use less medication).
To distinguish any hypoalgesic action of the TCET from reported 21 mood-enhancing eects, validated assessments often used to estimate depression and mood/anxiety 26, 27 were administered before and after sham or TCET.
The turnover of some neurochemicals/hormones often assayed in studies evaluating mood, depression and antidepressive treatments 28, 29 were also monitored. Experimental studies have implicated increased central noradrenaline (NA) turnover and the hypothalamo pituitary adrenal (HPA) axis in the antinociceptive action of this TCET. 30 Thus plasma adrenocortico trophic hormone (ACTH); salivary, plasma, and urinary cortisol were assayed before and after transcranial or sham treatment as objective indicators of the activity of the HPA axis in the treatment. 28 The plasma concentration and total urinary output during the sham and treatment period of the principal metabolite of NA, 3-methoxy-4-hydroxy-phenylglycol (MHPG) was assayed as an indication of whether central NA turnover was implicated in any observed eects of TCET. 29 The present study was conducted to evaluate the therapeutic ecacy of this novel transcranial stimulus to ameliorate suering. The additional assessments to determine the eect of TCET on mood/depression were conducted to indicate whether any observed analgesic action was secondary to a mood enhancing action or, as might be anticipated from the antinociceptive action in experimental animals, 22 ± 24 was an independent analgesic eect.
Materials and methods

Subjects
Paraplegic and tetraplegic individuals totalling 30 volunteers in all were located amongst their membership by the Spinal Injuries Association, London, UK. These subjects agreed to attend a residential centre (Hereward College, Coventry, UK which provides educational facilities for students with disabilities) on two separate occasions of 5 days, where they would receive 26TCET or 26sham treatments daily, one between 10.00 ± 12.00 h and the other 14.00 ± 16.00 h on 4 successive days. All participants agreed to record all medication used during the 3 days preceding, the 4-day test period and 7 days succeeding each arm of the study. All volunteers included also agreed to reduce and (if possible) cease using analgesic, anxiolytic or antidepressive medication 24 h prior to commencing TCET or sham treatment and to refrain from consuming alcohol during each sham or treatment period.
The participants comprised nine subjects with cervical, 16 with thoracic and the remainder with lumbar lesions. All subjects presented with a history of chronic pain described as neuropathic, nerve root entrapment, visceral, musculoskeletal and of undiagnosed origins. Smokers and subjects with other conditions or using medications contraindicating the (then) known exclusion criteria did not participate. Three of the 30 subjects included were withdrawn from the study after commencement, one of whom developed an upper respiratory infection, and two others were withdrawn from the study because their medication (either H2 antagonist anti-ulcer or steroidal inhalant) were interacting with the TCET treatment. All subjects were free to withdraw from the study, none voluntarily withdrew.
Study design
The study was designed to occur in two arms with an 8-week wash-out period between. Subjects would be randomly assigned into two groups according to their choice of treatment device. Thirty treatment devices were provided, 15 delivered TCET and 15 others (sham) appeared to be delivering treatment because the indicators functioned in the same manner as the TCET devices. The devices were numbered for identi®cation, but neither the administrators nor the recipients of the treatment could distinguish between the devices. On the ®rst arm of the test, before the ®rst session, the subjects were invited to choose a device. The chosen device remained with that subject throughout the study. It was anticipated that at the end of the ®rst arm of the study all the devices would be returned to the engineers for their functions to be reversed so that the TCET would become sham devices and vice versa. After an independent statistical analysis of the results of the ®rst arm of the study, it was decided to reverse only the sham treatment devices rather than withhold eective treatment from subjects who were being requested to cease using their existing medication. Therefore, on the second arm of the study, all the subjects received TCET treatment.
Equipment
TCET or sham treatment was administered by purpose-made portable signal generators constructed by Carex, Hemel Hempstead, UK. All devices had LEDs to indicate when treatment was, or was apparently (in the case of sham treatment) being delivered and when it was completed. An alarm indicated if the subject became inadvertently disconnected. TCET was eected via customised earpieces attached to each ear lobe. The earpieces contained pin electrodes that pierce only the outermost layers of the skin, facilitating a consistent low impedance.`Smart' circuitry within the device compensated for alterations in conduction and/or capacitance during treatment, so that every TCET-treated individual received an identical treatment paradigm. There were no user controls/adjustments on the equipment. The treatment cycle was initiated by the insertion of the lead connected to the earpieces into the device, the cranium of the subject completed the circuit, thus eecting the passage of an exact standardised current. All subjects were monitored while receiving TCET or sham treatment. Any subject who became disconnected was immediately reconnected. The sham and TCET treatment sessions lasted 53 min. Each TCET-treated subject received interrupted trains of charge-balanced impulses of positive amplitude 12 mA and positive duration 2.0 msec at a duty cycle of 10 cps. Both TCET and sham devices were tested on an oscilloscope before and after all treatment sessions.
Assessment procedures
The characteristics and intensity of the pain was assessed using the self-reported Short Form McGill Pain Questionnaire (SF-MPQ) 31 which provides a Pain Rating Index (PRI) based on the total score of adjective words selected by the subject; a Present Pain Index (PPI) based on a 0 ± 5 intensity scale and Visual Analogue Scale (VAS) based on the level of pain noted on a 10 cm scale line. Anxiety, depression and neuroticism are confounding characteristics that in¯u-ence pain perception and these were also determined by self-reporting. Anxiety was assessed using the Trait form X2 (comprising 20 statements scored on a 1 ± 4 intensity scale) of the Speilberger State and Trait Anxiety Inventory (STAI). 27 Only the Trait part of the STAI was used as it is relatively impervious to the conditions under which it is administered, whereas the State part of the STAI demands exact parameters not met in the study (eg quiet room, same time every day, etc.). The short form Beck Depression Inventory (BDI) 26 based on total score of 13 statements ranging in severity from 0 ± 3 was used to assess aective symptoms indicative of depression, and the Eysenck Personality Inventory (EPQ) 32 to screen for neuroticism. Subjects completed the SF-MPQ questionnaire before commencement and on ®nishing each treatment session on each of the 8 days of the study. The STAI, BDI and EPQ questionnaires were completed before commencement on the ®rst day and at the end of each of the 4-day periods on each arm of the study, where necessary assistance was provided by the nursing sta. The questionnaires were collated and forwarded to professional statisticians, Priority Search, Sheeld, UK, who analyzed the data after the ®rst and second arm of the study, unaware as to which group received TCET and which received sham treatment.
Dierences in medication use throughout the study were compared where possible. Some subjects had automatic delivery systems implanted, others reported not receiving any medication that would impact on suering, speci®cally, analgesics, antidepressants and anxiolytics, at the time of each arm of the study.
Assessment of medication use
The type of medication used was categorised by purpose as analgesic (including anti-in¯ammatory), anxiolytic including hypnotics and muscle relaxants, antidepressives, antispasmodics, antibiotics, cardiovascular agents, diuretics, laxatives, bulking agents, antiulcer therapy and HRT. Some subjects reported that their antidepressant medication, in particular tricyclic antidepressants (TCADs) were prescribed as analgesic adjuvants. Where, however, the dosage was prescribed at the level indicated for treatment of depression, the medication was categorised as antidepressive. The use of analgesics and combined anxiolytic/antidepressants before, during, and after receiving TCET or sham treatment, was compared in the same subjects.
Sample collection for assays Salivary samples (4 ml) were collected into tubes before commencement and immediately after completion of all TCET or sham treatments. These samples were immediately frozen in solid CO 2 for transportation and storage in liquid N 2 prior to assay.
Most of the participants had catheters and their urine collected into leg-bags. Subjects who were able to provide samples voided their bladder completely before and immediately after all TCET or sham treatments. Leg-bags were emptied completely prior to and immediately upon completion of TCET or sham treatment. The total volume of each sample was recorded and two separate aliquots of each sample (20 ml) frozen immediately in solid CO 2 prior to transportation and storage in liquid N 2 .
Blood (10 ml) was collected by venepuncture from the antecubital vein before the ®rst TCET or sham treatment prior to commencement of the ®rst, and after completion of the last session, on each procedure day. No haemolysed samples were accepted. Some subjects, after receiving one of the treatment paradigms, were dicult to sample even when using indwelling catheters. This was associated with an observed general decrease in blood pressure in one of the treatment groups. Whole blood, collected and placed into EDTA-coated tubes, was separated by centrifugation (1500 g av for 20 min at 28C). The resultant plasma was drawn o and aliquoted into two portions (2 ml) and frozen immediately in solid CO 2 for transportation and storage in liquid N 2 .
Assays
Operatives analysing plasma, saliva and urine samples were unaware of the regimen of treatment (TCET or sham) the subjects had received. Urinary, plasma and salivary cortisol concentration was determined by radioimmuno assay (RIA) using the antisera supplied in the Amerlex RIA kit provided by Amersham International plc (Amersham, UK), essentially by the method of Walker et al, 33 except that the salivary steroid was not extracted prior to assay, and the saliva was centrifuged to remove particulate matter. Plasma ACTH concentration was determined by RIA using the antisera and kit supplied by Incstar Corporation, Minnesota, USA. Plasma and urinary MHPG concentrations were determined by reversed-phase high performance liquid chromatography (HPLC) with electrochemical detection by a method based on that described by Taylor et al 34 after the conjugated MHPG had been completely hydrolysed essentially as described by Warnho. 35 
Statistical analysis
The average of reported pain values for each individual in the TCET or sham treated group following each treatment session was determined after each arm of the study. The statistical signi®cance of changes against time between the two groups for each of the 16 average values on each arm of the study was determined by Spearman Rank Correlation, and comparison between the pain intensity in the two groups at commencement of the ®rst arm was determined by the Fisher Exact Probability Test. The statistical signi®cance of dierences between medication use amongst the same subjects who received sham treatment on the ®rst arm of the study and TCET on the second arm were determined by a two-tailed Wilcoxon-Mann-Whitney test. The statistical signi®cance of dierences in the individual values of the concentration of cortisol, ACTH and MHPG in plasma after sham or TCET treatment, was determined by one-way ANOVA followed by Tukey's multiple comparison test. In the case of salivary cortisol concentration, each individual post-treatment value was expressed as a percentage of the corresponding pre-treatment value to lessen the in¯uence of individual variation between the subjects. The statistical signi®cance of percentage changes in the concentration of salivary cortisol following TCET or sham treatment over the corresponding pre-treatment value was determined by one-way ANOVA followed by Tukey's multiple comparison test. The statistical signi®cance of dierences in the individual values of total excretion of MHPG and cortisol in the urine after TCET or sham treatment was compared by one-way ANOVA followed by Tukey's multiple comparison test.
Results
Acceptance of treatment
Vital signs were taken of all subjects before and after completion of each TCET or sham session. No adverse reactions to either regimen were reported. Some subjects, speci®cally those receiving TCET, did report a feeling of relaxation that coincided with lowered blood pressure. Venepuncture was therefore not always possible post-TCET treatment.
Personality and mood variables
The scores of both groups on the four variables of the EPQ were compared and both groups did not dier signi®cantly from the reported population norm in extraversion, neurosis, psychosis and truthfulness. There were no signi®cant correlations between the overall pain improvement scores of individuals and each of the EPQ variables indicating that the hypoalgesic eects of the TCET were independent of personality variables. No signi®cant change associated with TCET against sham treatment was determined by comparison of the bipolar pro®le of mood states for anxiety, hostility, depression, lethargy, confusion and unsureness. A positive eect of the study was detected irrespective of the treatment (TCET or sham) implying that mood change was a non-speci®c event associated with the study but unrelated to treatment received.
Reported pain ratings
Comparison between the initial severity of reported pain on the ®rst arm of the study between the subjects before receiving TCET or sham treatment revealed no signi®cant dierence by the Fisher Exact Probability Test. The same comparison at the end of the ®rst arm of the study indicated that the reported intensity of the pain of the TCET treated subjects was signi®cantly lower (P=0.0016) than the dierent subjects who had received sham treatment. Subjects receiving sham treatment had no consistent change in reported pain over the 16 observations of the ®rst arm of the study (r s =1.17, P=0.50). Subjects receiving TCET treatment had consistent improvement (r s =0.86, P50.001) in their pain score on the SF-MPQ compared with the dierent subjects receiving sham treatment over the 16 observations on the ®rst arm of the study (Figure 1) . The same subjects receiving TCET on the second arm of the study, who had received sham treatment on the ®rst arm of the study, showed signi®cant (r s =0.68, P50.005) improvement over the 16 measurements when they received TCET (second arm) compared with when they received sham (®rst arm) of the study (Figure 2 ).
Reported drug usage
At commencement there was no signi®cant dierence in the average number of medications used by the same subjects on the ®rst arm (sham) and the second arm (TCET treatment), averaging 2.92 and 2.88 drug categories per person, respectively. Comparing the analgesic and combined anxiolytic and antidepressant drug usage on each arm of the study, however, the same subjects receiving TCET reported using signi®cantly (P50.05) less (46% of the average pretreatment level) analgesic medication and signi®cantly (P50.05) less (53%) of the average pre-treatment level of combined antidepressant and anxiolytic medication during the four treatment days (second arm) of the study. No signi®cant decrease in use of any of these medications occurred in the ®rst arm of the study when they received sham treatment. Furthermore, the reported use of these medications was signi®cantly (P50.05) reduced during the week succeeding TCET treatment but not during the week succeeding sham treatment (Figure 3 ). There were too few subjects reporting no drug usage at commence- Figure 1 The bars represent the average daily pain rating (mean of four measurements per day ± pre and post AM, pre and post PM session) for groups of dierent subjects receiving either Sham (n=13) or TCET (n=14) treatment (1st arm of study), expressed as a per cent of the baseline values. The baseline value is the summed and averaged pain(s) experienced by the subjects prior to commencement of the study. *Signi®cantly dierent (P50.05) from Sham value Figure 2 The bars represent the average daily pain rating (mean of four measurements per day ± pre and post AM, pre and post PM session) for groups of subjects receiving either Sham (®rst arm of study, n=13) or TCET (second arm of study, n=13) treatment, expressed as a per cent of the baseline values. The baseline value is the summed and averaged pain(s) experienced by the subjects prior to commencement of the study. *Signi®cantly dierent (P50.05) from Sham value Figure 3 The bars represent the average analgesic (TCET n=8, Sham n=6) and combined anxiolytic/antidepressant drug use (TCET n=10, Sham n=11) per day for groups of the same subjects receiving either Sham (®rst arm study) or TCET (second arm study) over 4 days; for 3 days preceding commencement of the study and for the 7 days following the study. *Signi®cantly dierent (P50.05) from Sham value ment of the study to determine whether there were any dierences in the eects of the TCET treatment in drug-free compared with medication-using participants.
Biochemical assays
Plasma assays There were no signi®cant dierences between plasma cortisol concentration before and after either treatment amongst dierent subjects, TCET versus sham ®rst arm of the study, or comparing the same group of subjects, ®rst versus second arm of the study. There was a signi®cant diurnal (F [7360]=13.06, P50.05) dierence between the morning and afternoon values ( Table 1) .
There were no signi®cant dierences between the actual ACTH concentrations comparing percentages (when the post-treatment was expressed as a percentage of the pre-treatment concentration) between subjects receiving sham or TCET treatment (Table 1) .
A high individual variation in plasma MHPG concentration before and after TCET or sham treatment was observed. No statistical dierences in plasma MHPG were observed between TCET and sham treatment in dierent subjects on the ®rst arm, or comparing the same subjects on the ®rst (sham) versus the second (TCET) arm of the study (Table 1) .
Salivary assays Large individual variations between salivary cortisol concentrations were observed. When the post-treatment concentration of steroid was expressed as a percentage of the pre-treatment value, marked dierences between the TCET and sham treated groups were noted. The average salivary concentration (post/pre value as per cent) of cortisol was signi®cantly (F [7424]=13.38, P50.05) lower in the dierent subject groups which received TCET compared with sham treatment (®rst arm of the study). The average salivary concentration of cortisol was signi®cantly (F[3204]=10.57, P50.05) lower than in the same subject groups which received TCET (on the second arm) than when they received sham treatment (on the ®rst arm of the study). There was no signi®cant dierence between the decreased salivary cortisol concentration when comparing the same subject groups receiving TCET on the ®rst and second arm of the study. The statistically signi®cant dierences in salivary cortisol concentration following TCET and sham treatment were apparent whether the morning and afternoon treatment sessions were compared separately or together (Table 1) .
Urinary assays Individual urinary cortisol excretion was extremely variable after morning or afternoon sham or TCET treatment. No signi®cant dierences between the same subjects receiving sham and TCET or in dierent subjects receiving sham or TCET was observed.
Considering the total MHPG excreted during sham or TCET treatment, and comparing the morning and afternoon treatment sessions separately, or together, all subjects receiving TCET excreted signi®cantly (F [7424]=17.88, P50.05) more MHPG in their urine. Urinary MHPG excretion was signi®cantly (F [3212]=24.56, P50.05) greater in subjects receiving TCET than sham treatment in the ®rst arm of the study, and signi®cantly higher (F [3204]=21.14, P50.05) when TCET was received on the second arm by subjects who had received sham in the ®rst arm of the study (Table 1) .
Discussion
The term`suering' has been described as a nebulous concept, 10 but such a`holistic' expression encompasses both the chronic pain 4 ± 9,13 and stressors, 11, 12 associated with SCI. Depression, for example, occurs in up to 40% of SCI subjects, and a recent review indicates post-traumatic stress disorder could be prevalent in 50% of the people with SCI. 36 Such psychobiological variables in¯uence the neurochemical response to medication 37 and these associated stressors could contribute to the intractable nature of the pain associated with SCI.
The medication use by SCI subjects is typically high 8 and their satisfaction with their treatment reportedly low. 9 Tolerance and/or dependence may develop to some medication used in the control of pain 14 and anxiety/depression, 38 and since many SCI subjects are relatively young, long-term management of SCI needs new developments.
Non-drug treatments such as TENS and spinal cord stimulation are administered to ameliorate pain. 15 ± 17 In view of the intricate involvement of psychological variables described in pain, transcranial treatment could provide 19 ± 22 a more comprehensive therapy for the management of SCI. The TCET species employed in the present studies was identi®ed using standard pharmaceutical testing models for the development of new analgesic agents. The administration of the stimulus under test conditions necessitated restraint procedures. 22, 23, 30 It was determined that the most eective antinociceptive signal did not elicit its response through mechanisms collectively described as Stress Induced Analgesia (SIA), rather, this TCET species ameliorated stress, and its antinociceptive action was temporally and neurochemically distinct from SIA 23, 30 being more similar to stimulation provoked analgesia (SPA). 24, 25 In the present study TCET treatment ameliorated SCI-associated pain reported in the recipients compared with sham treatment, but the psychological instruments employed indicate that the hypoalgesic eect was independent of changes in mood, whereas the biochemical indices indicated that the TCET has some similar neurochemical actions in the SCI subjects as in the experimental models. 30 The pain reported by the subjects included in the study was categorised into ®ve sub-divisions. With the relatively small sample size and the presence of more than one pain sub-type in most subjects it was not possible statistically to support greater ecacy for TCET in any particular pain sub-type compared with another. It was interesting to note that all the participants experiencing visceral pain/gut cramps voluntarily commented on bene®ts associated with TCET (but not sham) treatment.
The relatively small number of subjects, large individual variations, morning and afternoon dierences, and the diculties in sampling, diminished the value of the blood estimations, hence with the exception of total plasma cortisol, even diurnal dierences were not clearly apparent. However, salivary, ie free cortisol, was determined as a more sensitive index of changes in the HPA function than measuring total plasma cortisol. 28 Whereas lowered salivary cortisol has been associated with depression, 28 decreases in salivary cortisol have been associated with mood enhancement in certain groups of patients who had elevated salivary cortisol at the outset. 39 In the present study elevated cortisol would be anticipated as a consequence of chronic pain, the decreased concentration following TCET re¯ecting an ameliorating eect on the pain (stress) which provoked the raised cortisol excretion.
Urinary MHPG is often assayed 29, 40 as an index of central NA activity. The comparatively higher urinary MHPG output following TCET as opposed to sham treatment indicates increased turnover of NA and increased activity of this biogenic amine. Although the reports are not unequivocal, low levels of MHPG are usually associated with depressive spectrum disorder, 41 while raised nocturnal urinary MHPG has been observed in combat-related PTSD. 42 In the experimental studies 30 increased activity of NA (and in particular increased MHPG concentration) in dierent brain regions and activation of the feedback control exerted via the HPA axis is obligatory for the antinociceptive action of TCET.
It was concluded that the TCET was probably exerting a similar anti-stress action in the SCI subjects as in experimental studies, 23, 30 but dierences in mood enhancement comparing TCET and sham treatments were obscured by the psychosocial variables introduced by the study. 43 These were essentially positive reinforcements, such as environmental novelty, the high level of care and attention provided at the venue of the study and inter-individual support and social interactions with fellow SCI subjects, together with the active connection to a sham device which appeared to be functioning properly.
Another factor which could in¯uence mood was the voluntary self-reported withdrawal from analgesic, antidepressive and anxiolytic therapy during the study. Urinary MHPG excretion does alter in unipolar and bipolar depressed subjects receiving TCADs. 44 Therefore, the observed dierences in biochemical indices could have been a direct result of decreased drug use. The levels of those parameters, which showed consistently statistically signi®cant changes, namely salivary cortisol and urinary MHPG, were fairly constant pre-TCET treatment however, and the decrease in cortisol and increase in MHPG was seen immediately after TCET, but not sham treatment.
The same subjects who had received TCET had decreased requirements for some medication during treatment and on the week succeeding TCET, than during or after the arm of the study when they received sham treatment. This present TCET species has been demonstrated to reduce the abstinence eects associated with withdrawal from morphine in experimental models of addictive behaviour. 45, 46 It would therefore be anticipated that TCET could ameliorate the distressing symptoms associated with abrupt withdrawal from medication that the SCI subjects might have encountered. However, on a short-term (four successive days study) it is unsafe to conclude that this decreased requirement would be maintained. Drug usage, although higher than during the treatment period, was still signi®cantly less than their pre-study average in the week succeeding TCET. This increasing medication use in the subjects in the week after cessation of TCET treatment could have been exacerbated by negative aectivity 47 upon completion of the study, which could have increased the various chronic pain experiences returning in the absence of treatment. Alternatively, the participants could have voluntarily resumed their pre-study treatment regimens in the absence of further access to the TCET. Larger scale and longer-term studies are required to determine whether transcranial treatment could lower the longterm medication necessary for the management of the problems associated with SCI.
This study does suggest, however, that TCET treatment presently indicated for the amelioration of stress-related conditions and withdrawal from addictive substances could be useful in the management of pain and the overall suering associated with SCI, and that larger scale studies designed to evaluate speci®-cally bene®cial action on depression or PTSD in SCI should be conducted.
